Splenic hemangiosarcoma clinical trial at Johns Hopkins

“This is a clinical trial that will enroll a total of 9 dogs in order to evaluate the effects of an FDA-approved investigative agent on dogs that have splenic hemangiosarcoma. Safety and toxicology studies have been performed in healthy dogs. This is the first trial using the agent for treating canine hemangiosarcoma.

“Eligible dogs will have undergone surgical removal of the spleen at their local veterinary hospital. Following removal of the spleen, if the mass is diagnosed as hemangiosarcoma, the patient may be considered for enrollment. Dogs should weigh more than 10 kg (22 lbs) to be eligible for participation and be older than 1 year of age.”

For more information: Splenic hemangiosarcoma clinical trial at Johns Hopkins